American Century Companies’s Atara Biotherapeutics ATRA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-585
Closed -$23.6K 2847
2023
Q2
$23.6K Sell
585
-320
-35% -$18.1K ﹤0.01% 2782
2023
Q1
$63.3K Buy
905
+302
+50% +$29.3K ﹤0.01% 2601
2022
Q4
$49.4K Buy
+603
New +$62.8K ﹤0.01% 2539

Other funds holding ATRA

American Century Companies's ATRA Position: Q3 2023 in Review

American Century Companies sold out of Atara Biotherapeutics (ATRA) in Q3 2023, closing a stake of 585 shares — an estimated $23.6K sold.

American Century Companies first reported a position in ATRA in Q4 2022 and held it in 3 quarters. The position peaked at $63.3K in Q1 2023. 109 funds tracked by Wall St. Rank hold ATRA as of Q3 2023.

  • American Century Companies reported no remaining Atara Biotherapeutics position as of Q3 2023 after selling out during the quarter.
  • American Century Companies sold 585 Atara Biotherapeutics shares in Q3 2023, an estimated $23.6K.
  • American Century Companies first reported a position in Atara Biotherapeutics in Q4 2022 and held it in 3 quarters.
  • American Century Companies's Atara Biotherapeutics position peaked at $63.3K in Q1 2023.
  • 109 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q3 2023.

Based on American Century Companies's 13F filing for Q3 2023, filed 13 Nov 2023.